13721-01-2 Usage
Description
4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID is an organic compound that belongs to the quinoline family. It is characterized by its unique chemical structure, featuring a quinoline ring with an oxo group at the 4-position and a carboxylic acid group at the 3-position. 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID has garnered significant interest due to its potential applications in various fields, particularly in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID is used as a novel HIV-1 integrase strand transfer inhibitor for the treatment of HIV/AIDS. It works by inhibiting the integrase enzyme, which is crucial for the replication of the HIV virus within host cells. By blocking this enzyme, the compound prevents the integration of the viral DNA into the host genome, thereby suppressing the viral replication process and helping to manage the progression of the disease.
In addition to its application as an HIV-1 integrase inhibitor, 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID may also have potential uses in other therapeutic areas. However, further research and development are required to explore these possibilities and establish the compound's efficacy and safety in various medical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 13721-01-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,7,2 and 1 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 13721-01:
(7*1)+(6*3)+(5*7)+(4*2)+(3*1)+(2*0)+(1*1)=72
72 % 10 = 2
So 13721-01-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H7NO3/c12-9-6-3-1-2-4-8(6)11-5-7(9)10(13)14/h1-5H,(H,11,12)(H,13,14)
13721-01-2Relevant articles and documents
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
-
Page/Page column 114; 115, (2021/04/21)
The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
METHODS OF TREATMENT FOR CYSTIC FIBROSIS
-
, (2020/06/05)
This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. (I) The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.
Cyclopropanation–ring expansion of 3-chloroindoles with α-halodiazoacetates: Novel synthesis of 4-quinolone-3-carboxylic acid and norfloxacin
Peeters, Sara,Berntsen, Linn Neerbye,Rongved, P?l,Bonge-Hansen, Tore
supporting information, p. 2156 - 2160 (2019/09/30)
We present a short and efficient way of synthesizing two synthetically versatile 4-quinolone-3-carboxylate building blocks by cyclopropanation-ring expansion of 3-chloroindoles with α-halodiazoacetates as the key step. This novel transformation was applied towards the synthesis of the antibiotic drug norfloxacin.
